LONDON, July 12, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Circulating Tumor Cell (CTC) Diagnostics in US$.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
Download the full report: https://www.reportbuyer.com/product/4778754/
The report profiles 48 companies including many key and niche players such as - ApoCell, Inc.Biocep Ltd.Biocept, Inc.Biofluidica Microtechnologies LLCCelltraffix Inc.
Download the full report: https://www.reportbuyer.com/product/4778754/
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting LimitationsDisclaimersData Interpretation & Reporting LevelQuantitative Techniques & AnalyticsProduct Definitions and Scope of StudyII. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEWMarket OutlookClinical Relevance of CTCsCTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical BiopsyMajor Challenges in CTC DiagnosticsNeed for CTC Enrichment and Popular MethodsCTC Enrichment TechniquesSelect Available CTC Detection TechnologiesSelect CTC Isolation Systems - A Brief ComparisonCTC Identification - Various ApproachesCTC Identification ApproachesList of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor TypeCellSearch System™ - The First FDA Approved Automated Enrichment/Isolation TechniqueRising Incidence of Cancer - An Opportunity IndicatorTable 1: Worldwide Incidence of Cancer (2013, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)Table 2: New Cancer Cases in the World by Affected Site (2012) (In Thousands) (includes corresponding Graph/Chart)Cancer Prone Sites based on Age2. MARKET TRENDS AND DRIVERSLiquid Biopsy - the New Buzzword in HealthcareSelect Companies Active in Cancer Liquid BiopsyCTCs for Personalized Cancer TreatmentMicrofluidic Chip-based Technologies - A Promising Avenue for Cancer DiagnosisCTC Microdevices Hog the LimelightTable 3: Select CTC Microdevices and Their CharacteristicsIncreasing Research Reveal Further Complexities to CTC Composition and BehaviorEpCAM Glycoprotein - Insufficient for CTC DetectionNew Isolation Techniques Show Promise in Detecting EpCAM- Negative CTCsPhysical Property-based Enrichment Technologies Lose FizzEvidence in Favor CTC Heterogeneity Gains StrengthCTC Clusters Raise Research InterestDetection of EMTs Gains Precedence in the Backdrop of Recent Research FindingsLimitations of CTC Technology for Point-of- Care TestingCTC Technologies Offer an Edge over Imaging Tests for Breast Cancer PrognosisLimited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?Select Research Findings in Recent YearsMicrofluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and SpecificityNBiomics Makes its Contribution to CTC DiagnosisResearchers at University of Michigan Develop Revolutionary Capture CTCs MethodDean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker AnalysisGold Nanoparticles Help in the Detection of CTCs3. MEDICAL DIAGNOSTICS MARKET - A CONCEPTUAL OVERVIEWClinical DiagnosticsTable 4: Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)Table 5: Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)Molecular Diagnostics - Growth DriversMolecular Diagnostics for Lymphoid MalignanciesMarket Trends & IssuesGlobal Molecular Diagnostics on a High Growth CurveAutomation Driving Global MarketMolecular Diagnostics: Marking Convergence of Numerous TechnologiesAging Population, Disease Incidence - Fundamental Drivers of GrowthPharmaceutical Firms Carving their Niche in the Molecular Diagnostics MarketLimited Reimbursements by Third Party Payers - A Stumbling BlockMolecular Diagnostics and Intellectual PropertyBusiness Opportunities in the OffingMedical Training and Practice ChallengesHurdles All the Way for Companies Eyeing Molecular DiagnosticsIntegration of Molecular Diagnostics into TherapeuticsMolecular Diagnostics - Moving from Centralization to Decentralization4. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS - ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODSIntroductionEnrichmentFiltration (iSET)Density GradientImmuno-magnetic Cell EnrichmentAdvantages of Different CTC Enrichment ProceduresAdnaTestIdentification1. PCR-Based AnalysisReverse Transcriptase Polymerase Chain Reaction (RT-PCR)RT-qPCR2. Cytometric MethodsFiber-Optic Array Scanning Technology (FAST)Laser Scanning Cytometry (LSC)Flow CytometryCellSearchMaintrac®CTC-ChipEnzyme-linked Epithelial Immunospot Assay (ELISPOT)Fluorescence In Situ Hybridization (FISH)Vita-Assay®TelomeScan™CytoTrackSome Other Methods for Detection of CTCsCharacterizationChemo-Sensitivity Testing of CTCs5. PRODUCT LAUNCHES AND INTRODUCTIONSVortex Biosciences Launches VTX-1 Liquid Biopsy SystemVortex Biosciences Secures CE Mark and FDA Class I Registration for VTX-1 Liquid Biopsy SystemFluxion Biosciences Roll Out New CTC Recovery KitsBiocept Launches c-MET Amplification Detection TestBiocept Launches ROS1 Test for Identifying Suitable Therapeutic Targets for NSCLC6. RECENT INDUSTRY ACTIVITYMenarini-Silicon Inks Agreement to Take Over CELLSEARCH® CTC AssetsCancer Genetics and ApoCell Team Up for Cancer Profiling and Therapy SelectionGenomic Health Signs Commercial Agreement with Epic Sciences for AR-V7 Liquid Biopsy TestBGI Joins Hands with Clearbridge BioMedics to Market CTC Products in ChinaAbnova Secures License to CSV Monoclonal Antibody for CTC DetectionSorrento Secures License to CytoLumina's NanoVelcro CTC Profiling AssayJanssen Announces Utility of CELLSEARCH® System in PD-L1 Expression Detection on CTCsQiagen Acquires AdnaGen's CTC Enrichment TechnologyTokai Inks Deal with Qiagen for Licensing CTC Enrichment TechnologyScreenCell Enters Collaborative Study for Evaluating CTC Enrichment Capability of ScreenCell Products7. FOCUS ON SELECT PLAYERSApoCell, Inc. (US)Biocep Ltd. (Israel)Biocept, Inc. (US)Biofluidica Microtechnologies LLC (US)Celltraffix Inc. (US)Clearbridge Biomedics (Singapore)Creatv Microtech, Inc. (US)Cynvenio Biosystems, Inc. (US)Epic Biosciences Inc. (US)Fluxion Biosciences, Inc. (US)Ikonisys, Inc. (US)IVDiagnostics, Inc. (US)Janssen Diagnostics LLC (US)QIAGEN Hannover GmbH (Germany)RARECELLS SAS (Italy)ScreenCell (France)STEMCELL Technologies, Inc. (Canada)8. GLOBAL MARKET PERSPECTIVETable 6: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 7: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 8: World 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)III. MARKET1. THE UNITED STATESA.Market AnalysisUS Diagnostics Market: An OverviewCTC Diagnostics in the US - Set for a Strong GrowthApproved CTC Tests in the US - A Brief ComparisonCancer Incidence in the USTable 9: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)Table 10: Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart)Research Breakthroughs in the US CTC MarketProduct LaunchesStrategic Corporate DevelopmentsSelect PlayersB.Market AnalyticsTable 11: The US Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 12: The US Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)2. CANADAA.Market AnalysisCurrent and Future AnalysisCanadian Cancer StatisticsTable 13: New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)Table 14: New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart)Table 15: Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart)Stemcell Technologies, Inc. - A Key PlayerB.Market AnalyticsTable 16: Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 17: Canadian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)3. JAPANMarket AnalysisTable 18: Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 19: Japanese Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4. EUROPEA.Market AnalysisCurrent & Future AnalysisInsight into Molecular Diagnostics Markets in EuropeCancer TrendsTable 20: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)B.Market AnalyticsTable 21: European Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 22: European Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 23: European 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)4a. FRANCEA.Market AnalysisCurrent & Future AnalysisScreenCell - A Key PlayerB.Market AnalyticsTable 24: French Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 25: French Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4b. GERMANYA.Market AnalysisCurrent & Future AnalysisAn Overview of Molecular Diagnostics MarketStrategic Corporate DevelopmentKey PlayerB.Market AnalyticsTable 26: German Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 27: German Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4c. ITALYA.Market AnalysisCurrent & Future AnalysisRarecells Sas - A Key PlayerB.Market AnalyticsTable 28: Italian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 29: Italian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4d. THE UNITED KINGDOMMarket AnalysisTable 30: The UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 31: The UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4e. SPAINMarket AnalysisTable 32: Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 33: Spanish Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4f. RUSSIAMarket AnalysisTable 34: Russian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 35: Russian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4g. REST OF EUROPEMarket AnalysisTable 36: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 37: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)5. ASIA-PACIFICA.Market AnalysisCurrent & Future AnalysisCancer Trends in Asia-PacificTable 38: Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)Indian Molecular Diagnostics MarketChinaChinese Cancer StatisticsTable 39: New Cancer Cases in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)Table 40: Cancer Related Mortality in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)Strategic Corporate DevelopmentKey PlayerB.Market AnalyticsTable 41: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 42: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)6. REST OF WORLDA.Market AnalysisCurrent & Future AnalysisKey PlayerB.Market AnalyticsTable 43: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 44: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 48 The United States (31) Canada (3) Europe (10) - France (1) - Germany (6) - The United Kingdom (2) - Italy (1) Asia-Pacific (Excluding Japan) (3) Middle East (1)Download the full report: https://www.reportbuyer.com/product/4778754/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
Advertisement
Download the full report: https://www.reportbuyer.com/product/4778754/
The report profiles 48 companies including many key and niche players such as - ApoCell, Inc.Biocep Ltd.Biocept, Inc.Biofluidica Microtechnologies LLCCelltraffix Inc.
Download the full report: https://www.reportbuyer.com/product/4778754/
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting LimitationsDisclaimersData Interpretation & Reporting LevelQuantitative Techniques & AnalyticsProduct Definitions and Scope of StudyII. EXECUTIVE SUMMARY1. INDUSTRY OVERVIEWMarket OutlookClinical Relevance of CTCsCTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical BiopsyMajor Challenges in CTC DiagnosticsNeed for CTC Enrichment and Popular MethodsCTC Enrichment TechniquesSelect Available CTC Detection TechnologiesSelect CTC Isolation Systems - A Brief ComparisonCTC Identification - Various ApproachesCTC Identification ApproachesList of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor TypeCellSearch System™ - The First FDA Approved Automated Enrichment/Isolation TechniqueRising Incidence of Cancer - An Opportunity IndicatorTable 1: Worldwide Incidence of Cancer (2013, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)Table 2: New Cancer Cases in the World by Affected Site (2012) (In Thousands) (includes corresponding Graph/Chart)Cancer Prone Sites based on Age2. MARKET TRENDS AND DRIVERSLiquid Biopsy - the New Buzzword in HealthcareSelect Companies Active in Cancer Liquid BiopsyCTCs for Personalized Cancer TreatmentMicrofluidic Chip-based Technologies - A Promising Avenue for Cancer DiagnosisCTC Microdevices Hog the LimelightTable 3: Select CTC Microdevices and Their CharacteristicsIncreasing Research Reveal Further Complexities to CTC Composition and BehaviorEpCAM Glycoprotein - Insufficient for CTC DetectionNew Isolation Techniques Show Promise in Detecting EpCAM- Negative CTCsPhysical Property-based Enrichment Technologies Lose FizzEvidence in Favor CTC Heterogeneity Gains StrengthCTC Clusters Raise Research InterestDetection of EMTs Gains Precedence in the Backdrop of Recent Research FindingsLimitations of CTC Technology for Point-of- Care TestingCTC Technologies Offer an Edge over Imaging Tests for Breast Cancer PrognosisLimited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?Select Research Findings in Recent YearsMicrofluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and SpecificityNBiomics Makes its Contribution to CTC DiagnosisResearchers at University of Michigan Develop Revolutionary Capture CTCs MethodDean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker AnalysisGold Nanoparticles Help in the Detection of CTCs3. MEDICAL DIAGNOSTICS MARKET - A CONCEPTUAL OVERVIEWClinical DiagnosticsTable 4: Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)Table 5: Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)Molecular Diagnostics - Growth DriversMolecular Diagnostics for Lymphoid MalignanciesMarket Trends & IssuesGlobal Molecular Diagnostics on a High Growth CurveAutomation Driving Global MarketMolecular Diagnostics: Marking Convergence of Numerous TechnologiesAging Population, Disease Incidence - Fundamental Drivers of GrowthPharmaceutical Firms Carving their Niche in the Molecular Diagnostics MarketLimited Reimbursements by Third Party Payers - A Stumbling BlockMolecular Diagnostics and Intellectual PropertyBusiness Opportunities in the OffingMedical Training and Practice ChallengesHurdles All the Way for Companies Eyeing Molecular DiagnosticsIntegration of Molecular Diagnostics into TherapeuticsMolecular Diagnostics - Moving from Centralization to Decentralization4. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS - ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODSIntroductionEnrichmentFiltration (iSET)Density GradientImmuno-magnetic Cell EnrichmentAdvantages of Different CTC Enrichment ProceduresAdnaTestIdentification1. PCR-Based AnalysisReverse Transcriptase Polymerase Chain Reaction (RT-PCR)RT-qPCR2. Cytometric MethodsFiber-Optic Array Scanning Technology (FAST)Laser Scanning Cytometry (LSC)Flow CytometryCellSearchMaintrac®CTC-ChipEnzyme-linked Epithelial Immunospot Assay (ELISPOT)Fluorescence In Situ Hybridization (FISH)Vita-Assay®TelomeScan™CytoTrackSome Other Methods for Detection of CTCsCharacterizationChemo-Sensitivity Testing of CTCs5. PRODUCT LAUNCHES AND INTRODUCTIONSVortex Biosciences Launches VTX-1 Liquid Biopsy SystemVortex Biosciences Secures CE Mark and FDA Class I Registration for VTX-1 Liquid Biopsy SystemFluxion Biosciences Roll Out New CTC Recovery KitsBiocept Launches c-MET Amplification Detection TestBiocept Launches ROS1 Test for Identifying Suitable Therapeutic Targets for NSCLC6. RECENT INDUSTRY ACTIVITYMenarini-Silicon Inks Agreement to Take Over CELLSEARCH® CTC AssetsCancer Genetics and ApoCell Team Up for Cancer Profiling and Therapy SelectionGenomic Health Signs Commercial Agreement with Epic Sciences for AR-V7 Liquid Biopsy TestBGI Joins Hands with Clearbridge BioMedics to Market CTC Products in ChinaAbnova Secures License to CSV Monoclonal Antibody for CTC DetectionSorrento Secures License to CytoLumina's NanoVelcro CTC Profiling AssayJanssen Announces Utility of CELLSEARCH® System in PD-L1 Expression Detection on CTCsQiagen Acquires AdnaGen's CTC Enrichment TechnologyTokai Inks Deal with Qiagen for Licensing CTC Enrichment TechnologyScreenCell Enters Collaborative Study for Evaluating CTC Enrichment Capability of ScreenCell Products7. FOCUS ON SELECT PLAYERSApoCell, Inc. (US)Biocep Ltd. (Israel)Biocept, Inc. (US)Biofluidica Microtechnologies LLC (US)Celltraffix Inc. (US)Clearbridge Biomedics (Singapore)Creatv Microtech, Inc. (US)Cynvenio Biosystems, Inc. (US)Epic Biosciences Inc. (US)Fluxion Biosciences, Inc. (US)Ikonisys, Inc. (US)IVDiagnostics, Inc. (US)Janssen Diagnostics LLC (US)QIAGEN Hannover GmbH (Germany)RARECELLS SAS (Italy)ScreenCell (France)STEMCELL Technologies, Inc. (Canada)8. GLOBAL MARKET PERSPECTIVETable 6: World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 7: World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 8: World 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)III. MARKET1. THE UNITED STATESA.Market AnalysisUS Diagnostics Market: An OverviewCTC Diagnostics in the US - Set for a Strong GrowthApproved CTC Tests in the US - A Brief ComparisonCancer Incidence in the USTable 9: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)Table 10: Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart)Research Breakthroughs in the US CTC MarketProduct LaunchesStrategic Corporate DevelopmentsSelect PlayersB.Market AnalyticsTable 11: The US Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 12: The US Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)2. CANADAA.Market AnalysisCurrent and Future AnalysisCanadian Cancer StatisticsTable 13: New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)Table 14: New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart)Table 15: Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart)Stemcell Technologies, Inc. - A Key PlayerB.Market AnalyticsTable 16: Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 17: Canadian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)3. JAPANMarket AnalysisTable 18: Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 19: Japanese Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4. EUROPEA.Market AnalysisCurrent & Future AnalysisInsight into Molecular Diagnostics Markets in EuropeCancer TrendsTable 20: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)B.Market AnalyticsTable 21: European Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 22: European Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)Table 23: European 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)4a. FRANCEA.Market AnalysisCurrent & Future AnalysisScreenCell - A Key PlayerB.Market AnalyticsTable 24: French Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 25: French Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4b. GERMANYA.Market AnalysisCurrent & Future AnalysisAn Overview of Molecular Diagnostics MarketStrategic Corporate DevelopmentKey PlayerB.Market AnalyticsTable 26: German Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 27: German Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4c. ITALYA.Market AnalysisCurrent & Future AnalysisRarecells Sas - A Key PlayerB.Market AnalyticsTable 28: Italian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 29: Italian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4d. THE UNITED KINGDOMMarket AnalysisTable 30: The UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 31: The UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4e. SPAINMarket AnalysisTable 32: Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 33: Spanish Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4f. RUSSIAMarket AnalysisTable 34: Russian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 35: Russian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)4g. REST OF EUROPEMarket AnalysisTable 36: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 37: Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)5. ASIA-PACIFICA.Market AnalysisCurrent & Future AnalysisCancer Trends in Asia-PacificTable 38: Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)Indian Molecular Diagnostics MarketChinaChinese Cancer StatisticsTable 39: New Cancer Cases in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)Table 40: Cancer Related Mortality in China by Gender and Affected Site: 2015 (In Thousands) (includes corresponding Graph/Chart)Strategic Corporate DevelopmentKey PlayerB.Market AnalyticsTable 41: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 42: Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)6. REST OF WORLDA.Market AnalysisCurrent & Future AnalysisKey PlayerB.Market AnalyticsTable 43: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)Table 44: Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)IV. COMPETITIVE LANDSCAPETotal Companies Profiled: 48 The United States (31) Canada (3) Europe (10) - France (1) - Germany (6) - The United Kingdom (2) - Italy (1) Asia-Pacific (Excluding Japan) (3) Middle East (1)Download the full report: https://www.reportbuyer.com/product/4778754/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/global-circulating-tumor-cell-ctc-diagnostics---biotechnology-300487450.html
SOURCE ReportBuyer
